CHINARES PHARMA (03320): China Resources Sanjiu Medical & Pharmaceutical's net profit attributable to the parent company for the first half of the year is approximately 1.671 billion yuan, a year-on-year decrease of 7.96%.
China Resources Pharmaceutical (03320) announced the interim results of China Resources Sanjiu for 2026, with total revenue of approximately 15.014 billion yuan, a year-on-year increase of 1.37%; the net profit attributable to shareholders of the listed company was approximately 1.671 billion yuan, a year-on-year decrease of 7.96%; basic earnings per share were 1 yuan, with a cash dividend of 4.15 yuan per 10 shares (including tax).
CHINARES PHARMA (03320) announced that China Resources Sanjiu Medical & Pharmaceutical's mid-term performance for 2026 shows total revenue of approximately 15.014 billion yuan, a year-on-year increase of 1.37%; net profit attributable to shareholders of the listed company is approximately 1.671 billion yuan, a year-on-year decrease of 7.96%; basic earnings per share is 1 yuan, with a cash dividend of 4.15 yuan per 10 shares (tax inclusive).
Related Articles
CHINA ALUMCAN (06898) will distribute a mid-term dividend of HKD 0.002 per share on October 28.
Guolian Minsheng (01456): Ge Xiaobo resigns as the company's executive director and president.
KUAISHOU-W (01024) announced on August 21 that it spent HKD 150 million to repurchase 4.415 million shares.
CHINA ALUMCAN (06898) will distribute a mid-term dividend of HKD 0.002 per share on October 28.
Guolian Minsheng (01456): Ge Xiaobo resigns as the company's executive director and president.
KUAISHOU-W (01024) announced on August 21 that it spent HKD 150 million to repurchase 4.415 million shares.
RECOMMEND
